Related Experiment Videos
Identification of somatostatin receptors in human small cell lung carcinoma
U Sagman1, J B Mullen, K Kovacs
1Department of Medicine, Mount Sinai Hospital, Toronto, Canada.
Abstract:
Biopsy specimens obtained from eight patients with lung cancer were tested for content of somatostatin receptors by autoradiography. Somatostatin receptors were detected in two of three patients with small cell lung cancer (SCLC) but in none of five patients with non-small cell lung cancer (NSCLC) including adenocarcinoma (two), squamous cell carcinoma (two), and bronchoalveolar carcinoma (one). In those with SCLC, specific somatostatin receptor binding was evidenced only in tumor foci and not in surrounding stroma or normal lung parenchyma. Further tissue characterization by immunoperoxidase staining with the pancytokeratin monoclonal antibody, mAB-lu-5, revealed labeling to all of the NSCLC but to none of the SCLC specimen. Selective immunoreactivity was detected in both the SCLC and the NSCLC specimen to chromogranin and neuron-specific enolase (NSE) whereas none of the specimen had detectable immunostaining to somatostatin, bombesin, serotonin, adrenocorticotropic hormone, neurofilament, calcitonin, and synaptophysin. The identification of somatostatin receptors in primary human lung cancer may have a bearing on the biology of this disease and perhaps on the clinical application of somatostatin analogues in patients with SCLC.
Insights
Somatostatin receptors were found in small cell lung cancer (SCLC) but not in non-small cell lung cancer (NSCLC). This finding may influence future treatments for SCLC using somatostatin analogues.
Area of Science:
- Oncology
- Molecular Biology
- Medical Research
Background:
- Lung cancer is a leading cause of cancer-related mortality worldwide.
- Small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) are distinct subtypes with different prognoses and treatment strategies.
- Somatostatin receptors (SSTRs) are implicated in various cellular functions and have been explored as therapeutic targets.
Purpose of the Study:
- To investigate the presence and distribution of somatostatin receptors in primary human lung cancer specimens.
- To differentiate receptor expression between small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
- To explore the potential clinical implications of somatostatin receptor expression in lung cancer.
Main Methods:
- Biopsy specimens from eight lung cancer patients were analyzed.
- Autoradiography was used to detect somatostatin receptor content.
- Immunoperoxidase staining was performed using specific monoclonal antibodies (mAB-lu-5, chromogranin, NSE) for tissue characterization.
Main Results:
- Somatostatin receptors were detected in 2 out of 3 small cell lung cancer (SCLC) specimens.
- No somatostatin receptors were found in any of the 5 non-small cell lung cancer (NSCLC) specimens.
- Receptor binding in SCLC was localized to tumor foci, not surrounding tissues.
- All NSCLC specimens showed pancytokeratin labeling, while SCLC did not.
- Both SCLC and NSCLC expressed chromogranin and neuron-specific enolase (NSE).
Conclusions:
- Somatostatin receptors are present in a subset of small cell lung cancer (SCLC) but absent in non-small cell lung cancer (NSCLC).
- The specific localization of SSTRs in SCLC tumors suggests a potential role in tumor biology.
- These findings may inform the development of somatostatin analogue therapies for patients with SCLC.